Progressive myoclonic epilepsy type 5

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:402082OMIM:607459G40.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Progressive myoclonic epilepsy type 5 (PME5), also known as PRICKLE1-related progressive myoclonus epilepsy, is a very rare inherited neurological condition. It belongs to a group of disorders called progressive myoclonic epilepsies, which are characterized by seizures that worsen over time along with involuntary muscle jerking (myoclonus) and a gradual decline in brain function. In this condition, affected individuals typically develop myoclonic jerks — sudden, brief, shock-like muscle twitches — along with generalized tonic-clonic seizures (formerly called grand mal seizures). Over time, people with PME5 may also experience difficulties with coordination and balance (ataxia), cognitive decline, and problems with speech. The disease tends to get worse gradually, meaning symptoms become more severe and harder to control as time goes on. There is currently no cure for progressive myoclonic epilepsy type 5. Treatment focuses on managing seizures and myoclonus with anti-seizure medications, though seizures in progressive myoclonic epilepsies can be difficult to fully control. Supportive therapies such as physical therapy, occupational therapy, and speech therapy may help maintain function and quality of life for as long as possible. Research into the underlying genetic mechanisms continues, but disease-modifying treatments are not yet available.

Also known as:

Key symptoms:

Involuntary muscle jerking (myoclonus)Seizures, including generalized tonic-clonic seizuresProgressive loss of coordination and balance (ataxia)Cognitive decline over timeDifficulty with speechDifficulty walkingTremorMuscle stiffnessLoss of previously acquired skillsDifficulty with fine motor tasks like writing

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Progressive myoclonic epilepsy type 5.

View clinical trials →

No actively recruiting trials found for Progressive myoclonic epilepsy type 5 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Progressive myoclonic epilepsy type 5 community →

No specialists are currently listed for Progressive myoclonic epilepsy type 5.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Progressive myoclonic epilepsy type 5.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Progressive myoclonic epilepsy type 5Forum →

No community posts yet. Be the first to share your experience with Progressive myoclonic epilepsy type 5.

Start the conversation →

Latest news about Progressive myoclonic epilepsy type 5

No recent news articles for Progressive myoclonic epilepsy type 5.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type of progressive myoclonic epilepsy does my family member have, and how was the diagnosis confirmed?,What medications are recommended, and which ones should be avoided because they could make symptoms worse?,What is the expected course of this disease, and how quickly might symptoms progress?,What therapies (physical, occupational, speech) should we start now?,What should we do if a seizure lasts longer than 5 minutes?,Are there any clinical trials or research studies we could participate in?,Should other family members be tested for the PRICKLE1 gene variant?

Common questions about Progressive myoclonic epilepsy type 5

What is Progressive myoclonic epilepsy type 5?

Progressive myoclonic epilepsy type 5 (PME5), also known as PRICKLE1-related progressive myoclonus epilepsy, is a very rare inherited neurological condition. It belongs to a group of disorders called progressive myoclonic epilepsies, which are characterized by seizures that worsen over time along with involuntary muscle jerking (myoclonus) and a gradual decline in brain function. In this condition, affected individuals typically develop myoclonic jerks — sudden, brief, shock-like muscle twitches — along with generalized tonic-clonic seizures (formerly called grand mal seizures). Over time, pe

How is Progressive myoclonic epilepsy type 5 inherited?

Progressive myoclonic epilepsy type 5 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.